Project Grant R44CA290973
Award Date
9/2/24
Completion Date
8/31/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Woodinville, WA, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $1,022,522 to Isoprene Pharmaceuticals Inc. to develop their lead compound VNPP433-3B as a novel oral therapeutic for treating both primary and metastatic prostate cancer. The key objectives are to: 1) Synthesize 500g of non-GMP VNPP433-3B for preclinical studies, 2) Conduct additional pharmacology testing of VNPP433-3B using in vitro and in vivo prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research aimed at overcoming resistance to radiopharmaceutical therapy (RPT) in prostate cancer. The $404,972 award, effective August 1, 2025 through July 31, 2027, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how the tumor microenvironment, specifically the enzyme ENPP1, can limit the immune-activating effects of PSMA-targeted RPT....
This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $177,209 to Temple University to develop a class of chemical probes that can effectively inhibit c-Myc, an important target for treating castration-resistant prostate cancer (CRPC). The project aims to utilize a proprietary fluorine-thiol displacement reaction (FTDR) stapling technique to generate peptide mimetics that can disrupt c-Myc-Max heterodimerization and c-Myc-mediated...
The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...
The National Cancer Institute (NCI) awarded a $406,258 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Georgia State University Research Foundation Inc. on July 15, 2025. The grant supports research to develop novel covalent anti-cancer drugs using phosphorus fluoride exchange (PFEX) click chemistry. The key objectives are to: 1) synthesize PFEX warheads with different substituents to optimize stability and reactivity, 2) compare PFEX warheads to α,β-unsaturated carbonyl warheads,...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...